Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion

Progress in Neurobiology

Volumn 94, Issue 3, 2011, Pages 296-306

  Schrag, Matthew ^a   Mueller, Claudius ^b   Oyoyo, Udochukwu ^c   Smith, Mark A ^d   Kirsch, Wolff M ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Center for Applied Proteomics and Molecular Medicine   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Chelation; Citation bias; Meta analysis; Publication bias; Transition metals

Indexed keywords

COPPER; IRON; ZINC;

ALZHEIMER DISEASE; COPPER BLOOD LEVEL; DATA ANALYSIS; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; META ANALYSIS; NEOCORTEX; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; ZINC BLOOD LEVEL;

ALZHEIMER DISEASE; BIAS (EPIDEMIOLOGY); COPPER; DATABASES, FACTUAL; HOMEOSTASIS; HUMANS; IRON; MIDDLE AGED; OXIDATIVE STRESS; PERIODICALS AS TOPIC; ZINC;

EID: 79959395494     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.05.001     Document Type: Review

References (64)

1. Amit T., Avramovich-Tirosh Y., Youdim M., Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 2008, 22:1296-1305.
2. Atamna H. Amino acids variation in amyloid-beta peptides, mitochondrial dysfunction and new therapies for Alzheimer's disease. J. Bioenerg. Biomembr. 2009, 41:457-464.
3. Bax L., Yu L., Ikeda N., Moons K. A systematic comparison of software dedicated to meta-analysis of causal studies. BMC Med. Res. Methodol. 2007, 7:40.
4. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease. Neurobiol. Aging 1995, 16:661-674.
5. Brewer G. Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer's disease. Exp. Biol. Med. 2007, 232l:323-335.
6. Brunnstrom H., Englund E. Clinicopathological concordance in dementia diagnostics. Am. J. Geriatr. Psychiatry 2009, 17:664-670.
7. Bush A.I., Pettingell W.H., Multhaup G., Paradis M.D., Vonsattel J.P., Gusella J.F., Beyreuther K., Masters C.L., Tanzi R.E. Rapid induction of Alzheimer Abeta amyloid formation by zinc. Science 1994, 265:1464-1467.
8. Bush A. Metals and neuroscience. Curr. Opin. Chem. Biol. 2000, 4:184-191.
9. Chapman S., Ragg M., McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aust. N. Z. J. Psychiatry 2009, 43:277-282.
10. Chavhan G., Babyn P., Thomas B., Schroff M., Haacke M. Principles, techniques and applications of T2*-based MR imaging and its special applications. Radiographics 2009, 29:1433-1449.
11. Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 1999, 274:23223-23228.
12. Connor J., Lee S. HFE mutations and Alzheimer's disease. J. Alzheimer's Dis. 2006, 10:267-276.
13. Crapper McLachlan D., Kruck T., Kalow W., Andrews D.F., Dalton A.J., Bell M.Y., Smith W.L. Intramusclar desferrioxamine in patients with Alzheimer's disease. Lancet 1991, 337:1304-1308.
14. Cuajungco M.P., Faget K.Y., Huang X., Tanzi R.E., Bush A. Metal chelation as a potential therapy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 920:292-304.
15. Dexter D., Carayon A., Javoyagid F., Agid Y., Wells F.R., Daniel S.E., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114:1953-1975.
16. Ding B., Chen K.M., Ling H.W., Sun F., Li X., Wan T., Chai W.M., Zhang H., Zhan Y., Guan Y.J. Correlation of iron in the hippocampus with MMSE in patients with Alzheimer's disease. J. Magn. Res. Imaging 2009, 29:793-798.
17. Duval S., Tweedie R. A non-parametric trim and fill method of accounting for publication bias in meta-analysis. J. Am. Stat. Assoc. 2000, 95:89-98.
18. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected b y a simple, graphical test. BMJ 1997, 315:629.
19. Filiz G., Price K.A., Caragounis A., Du T., Crouch P.J., White A.R. The role of metals in modulating metalloprotease activity in AD brain. Eur. Biophys. J. 2008, 37:315-321.
20. Gay B., Taylor K., Hohl U., Tolnay M., Staehelin H. The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. J. Nutr. Health Aging 2008, 12:132-137.
21. Gerlach M., Ben-Shachar D., Reiderer P., Youdim M. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J. Neurochem. 1994, 63:793-807.
22. Goodman L. Alzheimer's disease: a clinico-pathologic analysis of 23 cases with a theory on pathogenesis. J. Nerv. Ment. Dis. 1953, 118:97-130.
23. Gotzsche P.C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Control. Clin. Trials 1989, 10:31-56.
24. Greenberg S.A. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009, 339:b2680.
25. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 1958, 3:41-51.
26. Hallgren B., Sourander P. The non-haemin iron in the cerebral cortex of Alzheimer's disease. J. Neurochem. 1960, 5:307-310.
27. Hamilton R. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10:378-384.
28. Hutchison B., Oxman A., Lloyd S. Comprehensiveness and bias in reporting clinical trials. Can. Fam. Phys. 1995, 41:1356.
29. Jellinger K., Paulus W., Grundke-Iqbal I., Peiderer P., Youdim M. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Parkinson's Dis. Demen. Sect. 1990, 2:327-340.
30. Jervis R.E., Landsberger S., Aufreiter S., Vanloon J.C., Lecomte R., Monaro S. Trace elements in wet atmospheric deposition: application and comparison of PIXE, INAA and graphite furnace AAS techniques. Int. J. Environ. Anal. Chem. 1985, 15:89-106.
31. Kjaergard L., Gluud C. Citation bias of hepato-biliary randomized clinical trials. J. Clin. Epidemiol. 2002, 55:407-410.
32. Kirsch W., McAuley G., Holshouser B., Petersen F., Ayaz M., Vinters H.V., Dickson C., Haacke E.M., Britt W., Larsen J., Kim I., Mueller C., Schrag M., Kido D. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J. Alzheimer's Dis. 2009, 17:599-609.
33. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., Ritchie C.W. Safety, efficacy and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease; a phase IIa, double blind randomized placebo controlled trial. Lancet Neurol. 2008, 7:779-786.
34. Lilliefors H. On the Kolmogorov-Smirnov test for normality with mean and variance unknown. J. Am. Stat. Assoc. 1967, 62:399-402.
35. Liu G., Men P., Perry G., Smith M.A. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol. 2010, 610:123-144.
36. Maccioni R., Rojo L., Fernandez J., Kuljis R. The role of neuroimmunomodulation in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2009, 1153:240-246.
37. Mandel, Silvia A. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate. J. Alzheimer's Dis. 2008, 15:211.
38. Markesbery W. Brain trace elements concentrations in aging. Neurobiol. Aging 1984, 5:19-28.
39. Markesbery W. The role of oxidative stress in Alzheimer's disease. Arch. Neurol. 1999, 56:1449-1452.
40. Milton N. Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment. Drugs Aging 2004, 21:81-100.
41. Nieminem P., Rucker G., Miettunen J., Carpenter J., Schumacher M. Statistically significant papers in psychiatry were cited more often than others. J. Clin. Epidemiol. 2007, 60:939-946.
42. Paris G., DeLeo G., Menozzi P., Gatto M. Region-based citation bias in science. Nature 1998, 396:210.
43. Perry G., Taddeo M., Petersen R., Castellani R., Harris P.L., Siedlack S.L., Cash A.D., Liu Q., Nunomura A., Atwood C.S., Smoth M.A. Adventiously bound redox active iron and copper are at the center f oxidative damage in Alzheimer's disease. Biometals 2003, 16:77-81.
44. Qian Z., Wang Q. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders. Brain Res. Rev. 1998, 27:257-267.
45. Rogers J., Bush A., Cho H., Smith D., Thomson A., Friedlich A., Lahiri D.K., Leedman P., Huang X., Cahill C.C. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer' disease. Biochem. Soc. Trans. 2008, 36:1282-1287.
46. Rottkamp C.A., Raina A.K., Zhu X., Gaier E., Bush A.I., Atwood C.S., Chevion M., Perry G., Smith M.A. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 2001, 30:447-450.
47. Rouault T., Cooperman S. Brain iron metabolism. Semin. Pediatr. Neurol. 2006, 13:142-148.
48. Schipper H. Glial HO-1 expressions, iron deposition and oxidative stress in neurodegenerative disease. Neurotox. Res. 1999, 1:57-70.
49. Schipper H. Heme-oxygenase-1: role in brain aging and neurodegeneration. Exp. Gerontol. 2000, 35:821-830.
50. Schipper H. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res. Rev. 2004, 3:265-301.
51. Schipper H., Gupta A., Szarek W. Suppresion of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr. Alzheimer Res. 2009, 6:424-430.
52. Schmidt L.M., Gotzsche P.C. Of mites and men: reference bias in narrative review articles-a systematic review. J. Fam. Pract. 2006, 54:334-338.
53. Schrag M., Dickson A., Jiffry A., Kirsch D., Vinters H.V., Kirsch W. The effect of formalin fixation on the levels of brain transition metals in archived samples. Biometals 2010, 23:1123-1127.
54. Schrag M., Crofton A., Zabel M., Jiffry A., Kirsch D., Dickson A., Mao X.W., Vinters H.V., Domaille D.W., Chang C.J., Kirsch W.M. Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease. JAD 2011, 24:137-149.
55. Schubert D., Chevion M. The role of iron in beta-amyloid toxicity. Biochem. Biophys. Res. Commun. 1995, 216:702-707.
56. Seglen P.O. From bad to worse: evaluation by journal impact. Trends Biochem. Sci. 1989, 14:326.
57. Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:9866-9868.
58. Squitti R., Rossini P.M., Cassetta E., Moffa F., Psqualetti P., Cortesi M., Colloca A., Rossi L., Finazzi-Agro A. d-penicillamine reduces serum oxidatitive stress in Alzheimer's disease patients. Eur. J. Clin. Invest. 2002, 32:51-59.
59. Stankiewicz J. Role of iron in neurotoxicity: a cause for concern in the elderly?. Curr. Opin. Clin. Nutr. Met. Care 2009, 12:22.
60. Takeda A., Itoyama Y., Kimpara T., Zhu X., Avila J., Dwyer B.E., Perry G., Smith M.A. Heme catabolism and heme oxygenase in neurodegenerative disease. Antioxid. Redox. Signal. 2004, 6:888-894.
61. Youdim M. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox. Res. 2008, 14:45.
62. Zecca L. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863.
63. Zheng J., Goessler W., Geiszinger A., Kosmus W., Chen B., Zhuang G., Xu K., Sui G. Multi-element determination in earthworms with instrumental neutron activation analysis and inductively coupled plasma mass spectrometry: a comparison. J. Radioanal. Nucl. Chem. 1997, 223:149-155.
64. Zhu W., Zhong W., Wang W., Zhan C., Wang C., Qi J., Wang J., Lei T. Quantitative MR phase corrected imaging to investigate increased brain iron deposition in patients with Alzheimer's disease. Radiology 2009, 253:497-504.